Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Core Insights - Merck's investigational oral PCSK9 inhibitor, Enlicitide, has shown significant efficacy in reducing LDL-C levels in adults with heterozygous familial hypercholesterolemia (HeFH) during the Phase 3 CORALreef trial [1] Group 1 - Enlicitide demonstrated a significant reduction in LDL-C levels in the trial participants [1] - The Phase 3 CORALreef trial specifically targeted adults diagnosed with HeFH [1] - The results indicate a promising potential for Enlicitide as a treatment option for managing cholesterol levels in this patient population [1]